Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
VX3
- Ownership
- Private
- Development stage
- Other
01
Overview
VX3 is an early-stage biotechnology company focused on the development of novel small molecule inhibitors for the treatment of cancer. The company's primary research efforts center on targeting the ubiquitin-proteasome system, specifically focusing on the inhibition of Ubiquitin-specific protease 1 (USP1). By targeting USP1, VX3 aims to disrupt DNA damage repair pathways in cancer cells, particularly those with specific genetic vulnerabilities such as BRCA mutations. The company is currently advancing its lead programs through pre-clinical development to address unmet needs in solid tumors, including breast and ovarian cancers.
- Therapeutic areas
- Oncology
- Modalities
- Small molecule
- Industry
- Biotech
Beyond the preview
Go deeper on VX3.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VX3.